Humana (NYSE:HUM) had its target price raised by equities researchers at Deutsche Bank from $259.00 to $270.00 in a research note issued to investors on Friday. The brokerage presently has a “hold” rating on the insurance provider’s stock. Deutsche Bank’s target price suggests a potential upside of 1.76% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Credit Suisse Group began coverage on shares of Humana in a research note on Thursday, November 2nd. They set a “neutral” rating and a $256.00 price objective on the stock. Zacks Investment Research lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 17th. ValuEngine cut shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Oppenheimer lifted their target price on shares of Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Morgan Stanley decreased their target price on shares of Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a report on Thursday, November 9th. Eight equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Humana currently has a consensus rating of “Buy” and a consensus target price of $269.68.

Shares of Humana (HUM) opened at $265.32 on Friday. Humana has a 52 week low of $203.36 and a 52 week high of $293.35. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.61 and a current ratio of 1.85. The company has a market cap of $37,903.62, a PE ratio of 22.70, a P/E/G ratio of 1.54 and a beta of 0.93.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, topping the consensus estimate of $2.00 by $0.06. Humana had a net margin of 4.55% and a return on equity of 16.13%. The business had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same quarter in the previous year, the firm posted $2.34 earnings per share. Humana’s quarterly revenue was up 2.4% on a year-over-year basis. analysts expect that Humana will post 13.85 EPS for the current fiscal year.

Humana declared that its board has authorized a stock repurchase plan on Thursday, December 14th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the insurance provider to repurchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s leadership believes its shares are undervalued.

In other news, VP Timothy S. Huval sold 1,382 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total transaction of $340,027.28. Following the completion of the transaction, the vice president now directly owns 11,557 shares of the company’s stock, valued at $2,843,484.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the transaction, the senior vice president now directly owns 9,888 shares of the company’s stock, valued at $2,432,151.36. The disclosure for this sale can be found here. Insiders have sold 10,115 shares of company stock valued at $2,501,627 over the last three months. 0.80% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in shares of Humana by 74.1% during the third quarter. Janus Henderson Group PLC now owns 2,729,248 shares of the insurance provider’s stock valued at $664,921,000 after purchasing an additional 1,161,661 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Humana by 11.4% during the fourth quarter. Wells Fargo & Company MN now owns 1,842,029 shares of the insurance provider’s stock valued at $456,951,000 after buying an additional 188,711 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Humana by 10.8% during the third quarter. Ameriprise Financial Inc. now owns 1,465,119 shares of the insurance provider’s stock valued at $356,960,000 after buying an additional 142,706 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Humana by 3.0% during the fourth quarter. Acadian Asset Management LLC now owns 1,043,303 shares of the insurance provider’s stock valued at $258,809,000 after buying an additional 30,812 shares during the last quarter. Finally, Capital International Investors increased its holdings in Humana by 8.8% during the third quarter. Capital International Investors now owns 760,500 shares of the insurance provider’s stock valued at $185,281,000 after buying an additional 61,500 shares during the last quarter. 94.39% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece of content was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://theolympiareport.com/2018/02/11/humana-hum-pt-raised-to-270-00-at-deutsche-bank.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.